<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03543241</url>
  </required_header>
  <id_info>
    <org_study_id>VAL-1006P(A)</org_study_id>
    <nct_id>NCT03543241</nct_id>
  </id_info>
  <brief_title>MyoStrain CMR Testing of Ischemia With Low Levels of Stress</brief_title>
  <official_title>MyoStrain CMR Testing of Ischemia With Low Levels of Stress</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Myocardial Solutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Myocardial Solutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, observational study evaluates the accuracy of stress testing with the
      MyoStrain SENC CMR Imaging System to detect myocardial ischemia and viability in patients
      with suspected coronary artery disease using low levels of stress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective, single center study evaluates the MyoStrain SENC CMR Imaging System for the
      detection of myocardial ischemia and viability during conventional Cardiac Magnetic Resonance
      (CMR) wall motion stress testing. Patients with known or suspected coronary artery disease
      and scheduled for cardiac catheterization will be consented for inclusion in the study and
      evaluated during stress testing with low dose Dobutamine as the stressor agent. Data obtained
      with the MyoStrain SENC CMR Imaging System will be for observational purposes and will not be
      used to alter patient management.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 8, 2017</start_date>
  <completion_date type="Actual">October 18, 2018</completion_date>
  <primary_completion_date type="Actual">September 12, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of Ischemic CAD Detection</measure>
    <time_frame>Up to coronary angiography within 1 month of standard CMR stress testing</time_frame>
    <description>Sensitivity of correctly identifying ischemic coronary artery disease based on cardiac catheterization results using low dose Dobutamine stress testing with MyoStrain software</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity of Ischemic CAD Detection</measure>
    <time_frame>Up to coronary angiography within 1 month of standard CMR stress testing</time_frame>
    <description>Specificity of correctly screening patients with ischemic coronary artery disease based on cardiac catheterization results using MyoStrain stress testing with low dose Dobutamine</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">13</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Myocardial Dysfunction</condition>
  <arm_group>
    <arm_group_label>MyoStrain</arm_group_label>
    <description>Patients with suspected CAD and scheduled for cardiac catheterization will receive traditional CMR wall motion stress testing with MyoStrain software analysis of myocardial ischemia and viability.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MyoStrain</intervention_name>
    <description>Prior to cardiac catheterization, patients will be stress testing with low dose Dobutamine to evaluate wall motion, segmental, and global myocardial strain at rest and under stress to determine the accuracy of detecting ischemia and viability of myocardial tissue.</description>
    <arm_group_label>MyoStrain</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with known or suspected coronary artery disease scheduled for cardiac
        catheterization.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Known or suspected Coronary Artery Disease

          -  Symptoms potentially due to CAD; stable angina

          -  Positive imaging stress test or negative stress test but typical angina or anginal
             equivalent

          -  Negative Troponin with unstable angina

          -  Invasive coronary angiography planned within 3 months of CMR

          -  Provided written consent

        Exclusion Criteria:

          -  Pregnancy

          -  Contraindication to Magnetic Resonance Imaging

          -  Prior allergy to Dobutamine

          -  Severe aortic stenosis

          -  Hypertrophic Cardiomyopathy

          -  Clinically significant Ventricular Tachycardia that would prohibit Dobutamine
             administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances Wood, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>WakeMed Health and Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>WakeMed</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2018</study_first_posted>
  <last_update_submitted>December 15, 2018</last_update_submitted>
  <last_update_submitted_qc>December 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Strain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

